Results 11 to 20 of about 15,603 (146)

Discovery and SAR analysis of phenylbenzo[d][1,3]dioxole-based proprotein convertase subtilisin/kexin type 9 inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry, 2022
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel therapeutic target for the development of cholesterol-lowering drugs.
Fahui Li, Lihui Zhang, Jinhong Feng, Lei Zhang   +3 more
doaj   +1 more source

Lipid Parameters and Proprotein Convertase Subtilisin/Kexin Type 9 in Healthy Lebanese Adults

Metabolites, 2022
Background: High levels of non-HDL cholesterol (non-HDL-C), triglycerides (TG), lipoprotein (a) (Lp(a)), and Proprotein convertase subtilisin/kexin type 9 (PCSK9) as well as low levels of HDL-C are strongly associated with cardiovascular disease (CVD ...
Marie-Hélène Gannagé-Yared, Elie Naous, Anis Al Achkar, Wadih Issa, Ghassan Sleilaty, Vanda Barakett-Hamade, Marianne Abifadel   +6 more
doaj   +1 more source

Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors [PDF]

Clinical Research in Cardiology Supplements, 2019
Lipoprotein(a) (Lp(a)) is an internationally accepted independent atherogenic risk factor. Details about its synthesis, many aspects of composition and clearance from the bloodstream are still unknown. LDL receptor (LDLR) (and probably other receptors) play a role in the elimination of Lp(a) particles.
Julius, U, Tselmin, S, Schatz, U, Fischer, S, Bornstein, S R   +4 more
openaire   +2 more sources

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis

Journal of Lipid Research, 2007
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protease that regulates low density lipoprotein receptor (LDLR) protein levels. The mechanisms of this action, however, remain to be defined.
Yue-Wei Qian, Robert J. Schmidt, Youyan Zhang, Shaoyou Chu, Aimin Lin, He Wang, Xiliang Wang, Thomas P. Beyer, William R. Bensch, Weiming Li, Mariam E. Ehsani, Deshun Lu, Robert J. Konrad, Patrick I. Eacho, David E. Moller, Sotirios K. Karathanasis, Guoqing Cao   +16 more
doaj   +1 more source

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia

Медицинский совет, 2021
Dyslipidemia makes a substantial contribution to the mortality as one of the leading pathogenetic factors for cardiovascular diseases. The nature and degree of the effect on the blood lipid spectrum may vary in the lipid-lowering drugs from different ...
A. A. Shikaleva, M. L. Maximov, N. M. Kiseleva   +2 more
doaj   +1 more source

P8 PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 LEVELS AND ARTERIAL FUNCTION

Artery Research, 2017
Purpose/Background/Objectives: Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are modestly but significantly associated with increased risk of total cardiovascular events.
Losif Koutagiar, Charalambos Vlachopoulos, Dimitrios Terentes-Printzios, John Skoumas, Nikitas Skliros, Magkas Nikolaos, Antigoni Miliou, Dimitrios Tousoulis   +7 more
doaj   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview [PDF]

The American Journal of Medicine, 2017
Proprotein convertase subtilisin/kexin type 9 inhibitors serve as a valuable addition to the armamentarium of lipid-lowering agents and have promising potential. By inhibiting the proprotein convertase subtilisin/kexin type 9 enzyme, this novel molecule leads to increased low-density lipoprotein receptor density and decreased circulation of low-density
Zachary R, Noel, Craig J, Beavers
openaire   +2 more sources

Proprotein Convertase Subtilisin/Kexin 9 Inhibitors

Journal of Cardiovascular Pharmacology and Therapeutics, 2014
Proprotein convertase subtilisin/kexin 9 (PCSK9) is part of the proteinase K subfamily of subtilases and plays a key role in lipid metabolism. It increases degradation of the low-density lipoprotein receptor (LDL-R), modulates cholesterol metabolism and transport, and contributes to the production of apolipoprotein B (apoB) in intestinal cells ...
Simona, Dragan, Maria-Corina, Serban, Maciej, Banach   +2 more
openaire   +2 more sources

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9

Journal of Lipid Research, 2008
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has gained attention as a key regulator of serum low density lipoprotein cholesterol (LDL-C) levels. This novel protease causes the degradation of hepatic low density lipoprotein receptors. In humans,
Holly E. Careskey, R. Aleks Davis, William E. Alborn, Jason S. Troutt, Guoqing Cao, Robert J. Konrad   +5 more
doaj   +1 more source

Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients

JACC: Case Reports, 2020
Standard lipid-lowering therapies in solid organ transplantations pose challenges due to interactions with immunosuppressants. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a new class of lipid-lowering therapies with ...
Bruce A. Warden, PharmD, Tina Kaufman, PhD, PA-C, Jessica Minnier, PhD, P. Barton Duell, MD, Sergio Fazio, MD, PhD, Michael D. Shapiro, DO, MCR   +5 more
doaj   +1 more source